Silo Pharma has announced it has advanced the formulation development for its therapeutic drug, SPC-15, which utilises ketamine.
The Psychedelic Access and Research Alliance (PAREA) has released a position statement calling on the EU to harness psychedelics in a bid to create innovation in...
In light of clinical research showing MDMA-assisted therapy as a potential treatment for PTSD, at PSYCH Symposium in the British Museum on 6 July a conversation...
Global investment firm Psych Capital has agreed to acquire 100% of the issued share capital of Shortwave Pharma Inc.,
Subanaesthetic intravenous ketamine has been shown to be as effective and not inferior to electroconvulsive therapy (ECT) for the treatment of non-psychotic, treatment-resistant depression.
The Royal College of Psychiatrists, Heroic Hearts and other leading mental health charities have written letters to the Veterans Minister and the Minister of State for...
The use of psychedelics in research has a long and storied history, dating back to the mid-20th century.
As the mental health crisis continues to escalate, those suffering from mental health issues are seeking new solutions to combat PTSD, depression, anxiety, trauma and other...
PTSD is typically thought of in relation to veterans of recent wars and victims of abuse, and psychedelics have been researched in the last decades to help with...
While psychedelic research has, to date, largely focused on mathematical modelling and resting-state neuroimaging, cognitive neuroscientists are bringing new rigour to the field through the use...